CDSCO Approves safety, efficacy data with DMC report for Novartis' antimalarial drug Cipargamin Dr. Divya Colin13 Sept 2024 12:30 PMNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the safety and...
Lung cancer drug: Natco Pharma submits ANDA for generic version of Novartis Tabrecta Ruchika Sharma30 Aug 2024 5:34 AMHyderabad: Natco Pharma Limited has announced its submission of an Abbreviated New Drug Application (ANDA) containing a paragraph IV certification...
Entresto: Novartis loses initial bid to block generic of blockbuster heart drug Ruchika Sharma14 Aug 2024 6:00 AMLondon: Novartis, a leading pharmaceutical company, has failed in its attempt to convince a federal court to block MSN Pharmaceuticals, a generic...
Novartis bags USFDA accelerated approval for Fabhalta for reduction of proteinuria in primary IgA nephropathy Ruchika Sharma8 Aug 2024 6:00 AMBasel: Novartis has announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Fabhalta (iptacopan), a...
CDSCO panel Approves Novartis Protocol Amendment proposal to study inclisiran Dr. Divya Colin4 Aug 2024 11:30 AMNew Delhi: The Subject Expert Committee SEC functional under the Central Drug Standard Control Organization (CDSCO) has approved the drug major...
CDSCO Panel Approves Novartis Protocol Amendment Proposal To Study Ruxolitinib and Panobinostat Dr. Divya Colin30 Jun 2024 12:00 PMNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the protocol...
CDSCO Panel Approves Novartis Protocol Amendment Proposal To Study Ianalumab Dr. Divya Colin28 Jun 2024 12:00 PMNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major...
Positive Phase III Results Emerge for Remibrutinib in Chronic Spontaneous Urticaria Treatment Medha Baranwal25 Jun 2024 2:30 PMUSA: In a significant development for patients suffering from chronic spontaneous urticaria (CSU), Novartis has released promising Phase III trial...
Sanofi names Audrey Duval Derveloy as Executive Vice President, Global Head of Corporate Affairs Ruchika Sharma22 Jun 2024 7:17 AMParis: Sanofi has announced the appointment of Audrey Duval Derveloy, a seasoned healthcare industry leader and Sanofi France's President as...
Iptacopan significantly reduce proteinuria in patients with C3 glomerulopathy, reveals APPEAR-C3G trial Dr. Kamal Kant Kohli1 Jun 2024 2:00 AMNovartis today presented results from the 6-month, double-blind period of the Phase III APPEAR-C3G study of Fabhalta (iptacopan) at the late-breaking...
Novartis Gets CDSCO Panel Nod to Study Iptacopan in Atypical Hemolytic Uremic Syndrome Dr. Divya Colin29 May 2024 12:30 PMNew Delhi: The drug major Novartis has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
CDSCO Panel grants Novartis Protocol Amendment Proposal to study Remibrutinib in Chronic Spontaneous Urticaria Dr. Divya Colin21 May 2024 12:00 PMNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the protocol...
